About Emtherapro
Emtherapro is a company based in Decatur (United States) founded in 2021 by Nicholas Seyfried, Allan Levey, and Duc Duong. Emtherapro has raised $3 million across 1 funding round. Emtherapro offers products and services including Precision Medicine Platform and AI Analytics Service. Emtherapro operates in a competitive market with competitors including Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and LabConnect, among others.
- Headquarter Decatur, United States
- Founders Nicholas Seyfried, Allan Levey, Duc Duong
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 1 rounds
-
Latest Funding Round
$3 M (USD), Seed
Sep 07, 2023
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Emtherapro
Emtherapro offers a comprehensive portfolio of products and services, including Precision Medicine Platform and AI Analytics Service.
Enables data generation and insights for developing therapies in neurodegenerative diseases
Uses machine learning for deriving actionable insights in drug discovery and trials
Funding Insights of Emtherapro
Emtherapro has successfully raised a total of $3M through 1 strategic funding round. The most recent funding activity was a Seed round of $3 million completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Emtherapro
Investment portfolio details for Emtherapro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Emtherapro
Detailed financials for Emtherapro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emtherapro Comparisons
Peer comparison for Emtherapro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Emtherapro
Emtherapro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Pharmaron, Lonza, Pfizer, Boehringer Ingelheim and LabConnect, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services for small molecules are provided.
|
|
| Locked | Locked | Locked |
CDMO services for pharma, biotech, and specialty ingredients are provided.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| Locked | Locked | Locked |
Generic drugs and clinical research services are provided globally.
|
|
| Locked | Locked | Locked |
Laboratory testing, clinical trial research, and biopharma services are provided.
|
|
| Locked | Locked | Locked |
AI powered scientific data management and workflow automation solutions
|
Detailed competitors of Emtherapro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emtherapro
Complete news archive for Emtherapro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emtherapro
Emtherapro was founded in 2021 and raised its 1st funding round 2 years after it was founded.
Emtherapro is headquartered in Decatur, United States.
Kiran Pandey is the current CEO of Emtherapro.
Emtherapro is a funded company, having raised a total of $3M across 1 funding round to date.
Emtherapro was founded in 2021 in Decatur, United States, as a contract research organization in the biotechnology and pharmaceutical sectors. Services encompass drug discovery, biomarker identification and validation, and clinical trials support. Operations are centered on these core areas to assist pharmaceutical development. Leadership includes co-founders Nicholas Seyfried as CSO, Allan Levey as President, and Duc Duong as COO, with Kiran Pandey serving as CEO.
Emtherapro offers Precision Medicine Platform and AI Analytics Service.